The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

Chih Chiang Chiu, Chun Hsin Chen, Bo Yu Chen, Shu Han Yu, Mong Liang Lu

研究成果: 雜誌貢獻文章同行評審

40 引文 斯高帕斯(Scopus)


The second generation antipsychotic drugs (SGAs) are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the time-dependent effects of olanzapine treatment on pancreatic beta cell function in SGA-naïve schizophrenic patients. Forty-two schizophrenic subjects received olanzapine therapy for 8. weeks and thirty-three of them completed the trial. Of whom 33 completers (21 male, mean ± SD age: 37.6 ± 8.0. years) were inpatients and unexposed to SGA. The metabolic parameters were quantitatively assessed at weeks 0, 2, 4, and 8 by the intravenous glucose tolerance test. After 56-day olanzapine treatment, subjects had significant increases in body weight and as well as in the levels of triglyceride, total cholesterol, and low-density lipoprotein. Insulin secretion significantly decreased at week 2, returned to baseline at week 4, and significantly increased at week 8. Of the total samples, 18.2% and 33.3% of them met the criteria for significant weight gain and metabolic syndrome after 8-week olanzapine treatment, respectively. This study indicates that olanzapine-treated schizophrenic patients displayed biphasic changes in insulin secretion to a hyperglycemic challenge. The results of this study support that olanzapine might directly influence pancreatic beta cell function.

頁(從 - 到)866-870
期刊Progress in Neuro-Psychopharmacology and Biological Psychiatry
出版狀態已發佈 - 8月 2010

ASJC Scopus subject areas

  • 生物精神病學
  • 藥理


深入研究「The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine」主題。共同形成了獨特的指紋。